ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0982

Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus

Jordan Jacquez1, Lisa Zhu1, Manpreet Singh1, Caroline Siegel2, Lori Sahakian1, Brian Skaggs1, Jennifer Grossman1 and Maureen McMahon1, 1University of California Los Angeles, Los Angeles, CA, 2Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Damage Index, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated benefit in multiple outcomes in systemic lupus erythematosus (SLE), including disease activity, flare rates, survival, and thrombotic events. Previous studies, however, assessed HCQ as a dichotomous variable and may have been confounded by discontinuation of HCQ in more severely ill patients. A better understanding of the impact of sustained HCQ use on key disease outcomes will allow clinicians to more accurately appraise the benefits and risks of continued use. We examined cumulative HCQ doses in a cohort of SLE patients to better assess the relationship with damage accrual. A lupus severity index (LSI) was employed to control for potential confounding from disease severity.

Methods: We studied a prospective cohort of 286 adult SLE patients, followed for a minimum of 10 years. The cumulative HCQ dose from time of diagnosis to last known follow-up was calculated via retrospective chart review. This value was then divided by SLE disease duration to give an average HCQ dose per year of disease duration (HCQ/yr). Disease damage was assessed using SLICC/ACR Damage Index (SDI) scores at baseline, 3, and 5 years after enrollment. The incidence of major adverse cardiovascular events (MACE) was defined as coronary artery disease, myocardial infarction, ischemic stroke, transient ischemic attack (TIA), or peripheral artery disease. A validated lupus severity index (LSI) was calculated. Student’s t-test and Spearman’s test were used for bivariate analysis. Logistic regression was used for multivariate analysis.

Results: The cohort was composed of 99% females (mean age 40.7 years). There was a statistically significant negative correlation between HCQ/yr and SDI at baseline, 3, and 5 years (Table 1). At all specified time points, patients with an SDI of zero had a higher mean HCQ/yr compared to patients with SDI >/=1 (p< 0.001)(Table 2). 68/286 (23.8%) of patients had at least one MACE during follow-up. Patients with a MACE had lower mean HCQ/yr compared to patients without MACE (p=0.03). The same pattern was seen when looking at cardiac events (p=0.04) and ischemic stroke (p=0.02)(Table 3). The LSI mean was significantly higher in patients with SDI >1 at baseline, 3, and 5 years (p < 0.009) and in patients with MACE (p=0.05). In a logistic regression model that included LSI and HCQ/yr, the odds of any MACE significantly decreased with higher mean HCQ/yr (OR 0.994, p=0.027).

Conclusion: We found an inverse association between average yearly HCQ dose and damage in our cohort of SLE patients. This was seen with overall damage accrual and more specifically with cardiovascular damage. When the LSI was applied to our cohort of patients, it proved to be a useful predictor of long-term damage accrual; however, when the LSI was applied as a potential confounder to the inverse association between higher mean HCQ/yr and MACE, the association was still significant. These findings reaffirm existing data on the benefits of HCQ use in SLE and provide additional support for the continuous use of HCQ at appropriate dosages over the course of disease unless clearly contraindicated.

Supporting image 1

Supporting image 2

HCQ = hydroxychloroquine; SD = standard deviation; SDI = SLICC/ACR damage index.
Note: HCQ 200 mg/day is equivalent to 73 grams/year, HCQ 300 mg/day is equivalent to 110 grams/year, HCQ 400 mg/day is equivalent to 146 grams/year.

Supporting image 3

HCQ = hydroxychloroquine; SD = standard deviation; MACE = major adverse cardiovascular event; TIA = transient ischemic attack.


Disclosures: J. Jacquez, None; L. Zhu, None; M. Singh, None; C. Siegel, None; L. Sahakian, None; B. Skaggs, None; J. Grossman, None; M. McMahon, None.

To cite this abstract in AMA style:

Jacquez J, Zhu L, Singh M, Siegel C, Sahakian L, Skaggs B, Grossman J, McMahon M. Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/effect-of-cumulative-hydroxychloroquine-dose-on-prevention-of-damage-progression-and-cardiovascular-events-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-cumulative-hydroxychloroquine-dose-on-prevention-of-damage-progression-and-cardiovascular-events-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology